NodThera is a biotechnology company developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. Led by an experienced management team, NodThera is leveraging new insights into NLRP3 biochemistry to build a platform of highly differentiated small molecule NLRP3 inhibitors. The company’s investors include Sofinnova Partners, 5AM Ventures, Epidarex Capital and F-Prime Capital Partners. NodThera was founded in 2016 and maintains offices in Cambridge, UK, Seattle, WA and Boston, MA.
